BioAge Labs

Citigroup <a href="https://www.cnbc.com/2025/10/22/citigroup-says-shares-of-this-obesity-drug-biotech-could-nearly-double.html">has started recommending</a> investors to buy shares of small-cap obesity drug developer BioAge Labs. The bank's analysts called promising the company's molecule, which it has just <a href="https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-first-participant-dosed-phase-1-clinical">started</a> testing on humans. Against this backdrop, BioAge shares <a href="https://finance.yahoo.com/quote/BIOA/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAANJzO7qhtq4ftfonGEodVUta3W7CcmJ8wkHgYAForTOSW-XBS4xlKF7KLyQk0L35CoYcX_jqygts2GD4qGMiFBIdNwS4SdNJF98C33sKbOp9lSNggPnmigup5BLKbWDPzB_A28f6kwvxv2u7wovLH2Nc3V4Qa7V3KMWqsBlp24tN">rose</a> more than 14%. Citigroup believes that they could rise by another 70%.

Citi was the first on Wall Street to believe in the startup BioAge. It is creating a cure for obesity

Tesla, Inc.

Tesla CEO fears being forced out of the company when he completes this project

Musk urged Tesla shareholders to pay him $1 trillion to create an "army of robots"

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: Washington stimulates rally in oil

Wall Street analysts on Tesla's quarterly results

'The worst is behind us': why will Tesla's weak results 'please the bears'?

The EU plans to impose a 19th package of sanctions on Oct. 23 to stop imports of Russian LNG by 2027

Oil soared 5% after new US sanctions. They will affect crude exports from Russia

Barron Trump, the 19-year-old son of the American president, <a href="https://www.independent.co.uk/news/world/americas/us-politics/barron-trump-tiktok-job-trump-advent-b2842539.html">may take a position</a> on the board of directors of the social network TikTok. The news broke in mid-October in the British media after a comment by Donald Trump's former SMM manager to the Daily Mail. Jack Advent, 23, who in the past helped the White House chief of staff make hype content for the video platform, said that now that the social network <a href="https://www.whitehouse.gov/fact-sheets/2025/09/fact-sheet-president-donald-j-trump-saves-tiktok-while-protecting-national-security/">had avoided</a> closure thanks to the president, he should have put more young people, including Barron, on the board. The readiness with which the media picked up on this insignificant occasion is not so much about trust in the speaker, but more about confidence that the American president, who has never been shy about combining political and business interests, is quite capable of taking such a step. Oninvest continues its series of publications about how the president's children are capitalizing on their father's name. In the new material - about the youngest child of Donald Trump

Trump Family Corp.: Barron Trump is a boy worth $150 million

Pop Mart International Group Limited

The volume of bearish bets on Pop Mart stock has increased sevenfold since the beginning of the fall

Shares of the Laboubou producer fell the most since April due to fresh doubts about growth

Meta Platforms, Inc.

International Business Machines Corporation

Reddit, Inc.

Brent crude oil futures soared almost 6% after new US sanctions affected Russia's largest crude producers. Meta laid off about 600 employees from its AI division. IBM posted gains: beating Wall Street forecasts, raising its full-year revenue guidance and reporting a record $9.5 billion in AI orders in its portfolio, while shares plummeted. These and other topics - in the review of key events for the morning of October 23.

Highlights for the morning: new US sanctions, Meta cuts AI staff, IBM grows, Reddit sues

Data

Minerva Neurosciences, Inc.

Quotes of Minerva Neurosciences, a micro-cap developer of a drug against negative symptoms in patients with schizophrenia, <a href="https://finance.yahoo.com/quote/NERV/">soared</a>&nbsp;140% in one day. The company, which is worth just $44.8 million on the Nasdaq, <a href="https://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-financing-200-million-advance">said</a>&nbsp;it had raised up to $200 million to complete trials of its drug and will, if they prove successful, file for approval and prepare for a commercial launch.

Minerva soars 140% on up to $200 mln raise to finish schizophrenia drug trial

Beyond Meat, Inc.

A short squeeze and social media campaigns by retail investors are behind it

'Symbol of rebellion': Beyond Meat stock rockets 466% in two days

NANO Nuclear Energy Inc.

Silex Systems Limited

Lightbridge Corporation

Many countries are rethinking past limits on nuclear power, given its role in meeting climate targets and bolstering energy security. In the U.S., a series of <a href="https://www.whitehouse.gov/presidential-actions/2025/05/ordering-the-reform-of-the-nuclear-regulatory-commission/#:~:text=(c)%25C2%25A0%2520Facilitate%2520the%2520expansion%2520of%2520American%2520nuclear%2520energy%2520capacity%2520from%2520approximately%2520100%2520GW%2520in%25202024%2520to%2520400%2520GW%2520by%25202050%253B">executive actions</a> in May 2025 set an explicit goal to quadruple nuclear capacity to 400 gigawatts by 2050. They direct federal agencies to strip out unnecessary red tape, accelerate licensing, and spur construction of new reactors and uranium-enrichment facilities. Washington’s aim is to revive the domestic fuel cycle and curb import reliance – note the U.S. still <a href="https://www.eia.gov/uranium/marketing/pdf/2024%20UMAR.pdf">buys</a>&nbsp;roughly 20% of its enriched uranium from Russia.

Which small caps are benefitting from surging demand for nuclear power?

Investors with a long-term horizon should take a closer look at shares of luxury home goods seller RH, <a href="https://www.fool.com/investing/2025/10/21/why-this-california-based-companys-stock-could-rew/">writes</a>&nbsp;Jeremy Bowman, an analyst at the Motley Fool. The company has faced a number of challenges, leading to a major fall in its share price since the highs reached during the pandemic. But it has several drivers of growth – from expansion into Europe to launching new businesses – that could turn things around, Bowman argues.

The Motley Fool spotlights mid-cap luxury goods retailer RH for patient investors

NeuroSense Therapeutics Ltd.

Noble Capital Markets has initiated coverage of NeuroSense Therapeutics with an “outperform” rating and a target price of $9 per share. Thus, it estimates the micro-cap developer of an amyotrophic lateral sclerosis therapy could rise 620% from current levels. The analysts cite mid-stage trial results of the company’s lead drug PrimeC, which open the way for accelerated registration and earlier commercialization.

Noble initiates on ALS drugmaker NeuroSense with 'outperform', TP for 600% upside


Small Caps

Important news and analysis of global markets: stocks, crypto, bonds, ETF